CARGO Therapeutics (CRGX) Stock Price, News & Analysis

Company Overview

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $4.10 to $4.36
• 50-Day Range: $3.84 to $4.75
• 52-Week Range: $3.00 to $25.45
• Volume: 180,643 shs
• Average Volume: 571,275 shs
• Market Capitalization: $195.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

CARGO Therapeutics Stock Analysis - MarketRank™

CARGO Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 746th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

CARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CARGO Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CARGO Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CARGO Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CARGO Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRGX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CARGO Therapeutics does not currently pay a dividend.

Dividend Growth

CARGO Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRGX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.92% of the stock of CARGO Therapeutics is held by insiders.

Percentage Held by Institutions

93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRGX Stock Analysis - Frequently Asked Questions

How have CRGX shares performed this year?

CARGO Therapeutics' stock was trading at $14.42 at the beginning of 2025. Since then, CRGX shares have decreased by 70.5% and is now trading at $4.25.
View the best growth stocks for 2025 here.

How were CARGO Therapeutics' earnings last quarter?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.26.

When did CARGO Therapeutics IPO?

CARGO Therapeutics (CRGX) raised $281 million in an IPO on Friday, November 10th 2023. The company issued 18,750,000 shares at a price of $15.00 per share.

Who are CARGO Therapeutics' major shareholders?

CARGO Therapeutics' top institutional shareholders include Cormorant Asset Management LP (7.33%), Nantahala Capital Management LLC (2.39%), Wellington Management Group LLP (2.24%) and Woodline Partners LP (1.84%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan.
View institutional ownership trends.

How do I buy shares of CARGO Therapeutics?

Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CARGO Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 6/24/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRGX
• Previous Symbol: NASDAQ:CRGX
• CIK: 1966494
• Web: cargo-tx.com
• Phone: 650-379-6143
• Fax: N/A
• Employees: 116
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $33.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +263.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$167.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -45.93%
• Return on Assets: -39.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.30
• Quick Ratio: 6.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.83 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 46,110,000
• Free Float: 44,764,000
• Market Cap: $190.43 million
• Optionable: N/A
• Beta: 0.31